France Archives

News and Trends 30 Jun 2015

Stallergenes and Greer to create the World Leader in Allergy Immunotherapy

A few months ago, we were talking about the refusal of Stallergenes’ minority shareholders to merge with Greer laboratories, another competitor within the field of allergy treatment. Finally, Stallergenes shareholders accepted, and both companies are going to create the world leader in allergy immunotherapy. After the sale of Serono to Merck back in 2007, the magnate Ernesto Bertarelli started its […]

June 30, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 30 Jun 2015

Oldest French Biotech Transgene is One Step Closer to Bankruptcy

Transgene, the oldest French Biotech company announced just yesterday that it will cut 120 jobs on its current 300 employees. The company will shut down its manufacturing facility in order to focus on the Research and Development of its therapeutic vaccine candidates. Wise move or final last words? Back in 1976, Robert Swanson and Herbert Boyer founded […]

June 30, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 25 Jun 2015

Video: Discover How CAR-T Therapies are Working

It’s becoming a habit for us to talk about CAR-T therapies. It’s basically the next wave of treatments against cancer and already promises to be the future blockbusters and growth drivers of the whole Biotech industry. Cellectis, a leading company in this field, just published a cool video about CAR-Ts. Of course, they’re describing more specifically their own therapy, […]

June 25, 2015 - 1 minutemin - By Joachim Eeckhout

News and Trends 23 Jun 2015

DBV Technologies to cure Peanut allergy

DBV Technologies plans the initiation of its phase III clinical trial for Viaskin Peanut, after a satisfactory conclusion of the phase II. The drug candidate already achieved a positive opinion from the Paediatric Committee of the European Medicines Agency. Both FDA and EMA desire to move forward with the development of what may be the […]

June 23, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 19 Jun 2015

Servier disburses €114 Million for Taiho’s Colorectal Cancer treatment

Servier is fattening up its oncology assests with the acquisition of Taiho Pharmaceutical’s treatment of refractory mestatic colorectal cancer. The French laboratories will commercialize the molecule in Europe and other countries. Taiho Pharmaceutical and Servier come to an agreement for the development and commercialization of TAS-102 in Europe. The drug is an oral combination anticancer drug […]

June 19, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 17 Jun 2015

Deinove to challenge the Carotenoid Business

Carotenoids are powerfull antioxidants and essential in the production of vitamin A. The French synthetic biology biotech Deinove signed an agreement with the Canadian company POS Bio-Sciences with the hope of initiating a major breakthrough to the carotenoid market. Produced by all green plants, algae, some fungi and cyanobacteria, carotenoid is a group of more than 600 known […]

June 17, 2015 - 3 minutesmins - By Joachim Eeckhout

diabetes type 2 sanofi novo nordisk eli lilly

News and Trends 11 Jun 2015

Pharmas step on the gas chasing the next blockbuster in Type 2 Diabetes

Hundreds of millions of people all over the word suffer from type 2 Diabetes and the competition between pharma companies is fierce. Amongst them, Sanofi must think that good things come to those who wait. After years of delay, the French colossus is convinced with the Phase IIIb results on its type 2 diabetes treatment. […]

June 11, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 10 Jun 2015

French collaboration to develop Oncology-targeted Therapy

PEP-Therapy and CleveXel Pharma will co-develop targeted therapy in oncology. The product is based on an innovative technology involving bi-functional peptides that penetrate cells, and specifically block pathological mechanisms without affecting physiological mechanisms. The drug candidate is a cell-penetrating peptide that targets an interaction between two intracellular proteins, Caspase-9 and PP2A. It has been validated […]

June 10, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 9 Jun 2015

Kurma Partners announces the launch of its third fund Kurma Diagnostics

Kurma Diagnostics (KDx), the first Venture Capital fund dedicated to financing early-stage European innovative Diagnostic projects and companies, is here to stay. The firm Kurma Partners, author of this initiative, has received the support from several European and French institutions. The fund has raised €33 Million in its first fundraising round. KDx is a venture […]

June 9, 2015 - 2 minutesmins - By Nicolas Sainte-Foie

News and Trends 8 Jun 2015

Review: The Emerging Field of Bioluminescence

Thanks to the synthetic biology revolution, bioluminescence is now moving from a curious natural trait to an interesting research field that could soon arrive to the market. Bioluminescence’s impulsors aim at replacing electric lighting. Sounds good, but which are the most advanced projects right now? Will bioluminescence really have an impact on the lighting market and […]

June 8, 2015 - 4 minutesmins - By Philip Hemme

News and Trends 5 Jun 2015

Abivax launched an Euronext IPO to build up its anti-viral portfolio

Abivax has ended the paperwork and launched its IPO on Euronext Paris, where the biotech company plans to raise €43.6M. The clinical stage biotech is focused on developing anti-viral compounds and human vaccines. The French biotech want to insufflate the raised cash in its three developing products. Data from the two most advanced ones, ABX203 and ABX464, suggest that […]

June 5, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 3 Jun 2015

Erytech successfully completed its Phase III to ‘starve’ cancer cells to death

Erytech Pharma reported optimistic Phase III results of its pivotal program with GRASPA, an original treatment that targets cancer cells through “tumor starvation”. The positive results were presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO). Erytech Pharma’s technology makes it possible to “starve” cancer cells by depriving them of […]

June 3, 2015 - 2 minutesmins - By Lourdes Riquelme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us